Susquehanna International Group’s Aimmune Therapeutics AIMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-92,400
| Closed | -$3.18M | – | 12113 |
|
|
2020
Q3 | $3.18M | Sell |
92,400
-26,700
| -22% | -$569K | ﹤0.01% | 3750 |
|
|
2020
Q2 | $1.99M | Buy |
119,100
+25,500
| +27% | +$433K | ﹤0.01% | 4508 |
|
|
2020
Q1 | $1.35M | Buy |
93,600
+60,900
| +186% | +$1.56M | ﹤0.01% | 4711 |
|
|
2019
Q4 | $1.09M | Sell |
32,700
-40,800
| -56% | -$1.14M | ﹤0.01% | 5358 |
|
|
2019
Q3 | $1.54M | Buy |
73,500
+30,800
| +72% | +$629K | ﹤0.01% | 4754 |
|
|
2019
Q2 | $889K | Buy |
42,700
+24,100
| +130% | +$496K | ﹤0.01% | 5939 |
|
|
2019
Q1 | $416K | Buy |
+18,600
| New | +$438K | ﹤0.01% | 6624 |
|
|
2018
Q4 | – | Sell |
-120,800
| Closed | -$3.29M | – | 10412 |
|
|
2018
Q3 | $3.29M | Buy |
120,800
+45,500
| +60% | +$1.29M | ﹤0.01% | 3230 |
|
|
2018
Q2 | $2.02M | Sell |
75,300
-42,400
| -36% | -$1.3M | ﹤0.01% | 3994 |
|
|
2018
Q1 | $3.75M | Buy |
117,700
+76,100
| +183% | +$2.68M | ﹤0.01% | 2918 |
|
|
2017
Q4 | $1.57M | Sell |
41,600
-69,000
| -62% | -$2.23M | ﹤0.01% | 4366 |
|
|
2017
Q3 | $2.74M | Buy |
110,600
+99,700
| +915% | +$2.15M | ﹤0.01% | 3368 |
|
|
2017
Q2 | $224K | Hold |
10,900
| – | – | ﹤0.01% | 8095 |
|
|
2017
Q1 | $237K | Sell |
10,900
-21,400
| -66% | -$439K | ﹤0.01% | 7756 |
|
|
2016
Q4 | $661K | Buy |
+32,300
| New | +$660K | ﹤0.01% | 6394 |
|
Susquehanna International Group's AIMT Position: Q4 2020 in Review
Susquehanna International Group sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 238,307 shares — an estimated $8.21M sold.
Susquehanna International Group first reported a position in AIMT in Q3 2015 and held it in 15 quarters. The position peaked at $8.21M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.
- Susquehanna International Group reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
- Susquehanna International Group sold 238,307 Aimmune Therapeutics shares in Q4 2020, an estimated $8.21M.
- Susquehanna International Group first reported a position in Aimmune Therapeutics in Q3 2015 and held it in 15 quarters.
- Susquehanna International Group's Aimmune Therapeutics position peaked at $8.21M in Q3 2020.
- 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.
Based on Susquehanna International Group's 13F filing for Q4 2020, filed 16 Feb 2021.